Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Abstract Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely contributing to tumor immune evasion. The deregulation mainly arises from the potentiated pro-angiogenic factors secretion and can also target immune cells' biological events, such as migration and acti...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-04-01
|
| Series: | Cell Communication and Signaling |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12964-022-00838-y |
| _version_ | 1811260853902639104 |
|---|---|
| author | Mohammad Javed Ansari Dmitry Bokov Alexander Markov Abduladheem Turki Jalil Mohammed Nader Shalaby Wanich Suksatan Supat Chupradit Hasan S. AL-Ghamdi Navid Shomali Amir Zamani Ali Mohammadi Mehdi Dadashpour |
| author_facet | Mohammad Javed Ansari Dmitry Bokov Alexander Markov Abduladheem Turki Jalil Mohammed Nader Shalaby Wanich Suksatan Supat Chupradit Hasan S. AL-Ghamdi Navid Shomali Amir Zamani Ali Mohammadi Mehdi Dadashpour |
| author_sort | Mohammad Javed Ansari |
| collection | DOAJ |
| description | Abstract Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely contributing to tumor immune evasion. The deregulation mainly arises from the potentiated pro-angiogenic factors secretion and can also target immune cells' biological events, such as migration and activation. Owing to this fact, angiogenesis blockade therapy was established to fight cancer by eliminating the nutrient and oxygen supply to the malignant cells by impairing the vascular network. Given the dominant role of vascular-endothelium growth factor (VEGF) in the angiogenesis process, the well-known anti-angiogenic agents mainly depend on the targeting of its actions. However, cancer cells mainly show resistance to anti-angiogenic agents by several mechanisms, and also potentiated local invasiveness and also distant metastasis have been observed following their administration. Herein, we will focus on clinical developments of angiogenesis blockade therapy, more particular, in combination with other conventional treatments, such as immunotherapy, chemoradiotherapy, targeted therapy, and also cancer vaccines. Video abstract |
| first_indexed | 2024-04-12T18:53:54Z |
| format | Article |
| id | doaj.art-54b9ab4488744e86b8ec35814ea2f588 |
| institution | Directory Open Access Journal |
| issn | 1478-811X |
| language | English |
| last_indexed | 2024-04-12T18:53:54Z |
| publishDate | 2022-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell Communication and Signaling |
| spelling | doaj.art-54b9ab4488744e86b8ec35814ea2f5882022-12-22T03:20:24ZengBMCCell Communication and Signaling1478-811X2022-04-0120112310.1186/s12964-022-00838-yCancer combination therapies by angiogenesis inhibitors; a comprehensive reviewMohammad Javed Ansari0Dmitry Bokov1Alexander Markov2Abduladheem Turki Jalil3Mohammed Nader Shalaby4Wanich Suksatan5Supat Chupradit6Hasan S. AL-Ghamdi7Navid Shomali8Amir Zamani9Ali Mohammadi10Mehdi Dadashpour11Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz UniversityInstitute of Pharmacy, Sechenov First Moscow State Medical UniversityTyumen State Medical UniversityFaculty of Biology and Ecology, Yanka Kupala State University of GrodnoBiological Sciences and Sports Health Department, Faculty of Physical Education, Suez Canal UniversityFaculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal AcademyDepartment of Occupational Therapy, Faculty of Associated Medical Sciences, Chiang Mai UniversityInternal Medicine Department, Division of Dermatology, Albaha UniversityImmunology Research Center (IRC), Tabriz University of Medical SciencesShiraz Transplant Center, Abu Ali Sina Hospital, Shiraz University of Medical SciencesDepartment of Neurology, Imam Khomeini Hospital, Urmia University of Medical SciencesDepartment of Medical Biotechnology, Faculty of Medicine, Semnan University of Medical SciencesAbstract Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely contributing to tumor immune evasion. The deregulation mainly arises from the potentiated pro-angiogenic factors secretion and can also target immune cells' biological events, such as migration and activation. Owing to this fact, angiogenesis blockade therapy was established to fight cancer by eliminating the nutrient and oxygen supply to the malignant cells by impairing the vascular network. Given the dominant role of vascular-endothelium growth factor (VEGF) in the angiogenesis process, the well-known anti-angiogenic agents mainly depend on the targeting of its actions. However, cancer cells mainly show resistance to anti-angiogenic agents by several mechanisms, and also potentiated local invasiveness and also distant metastasis have been observed following their administration. Herein, we will focus on clinical developments of angiogenesis blockade therapy, more particular, in combination with other conventional treatments, such as immunotherapy, chemoradiotherapy, targeted therapy, and also cancer vaccines. Video abstracthttps://doi.org/10.1186/s12964-022-00838-yAngiogenesisTumorAnti-angiogenic agentsCombination therapyResistance |
| spellingShingle | Mohammad Javed Ansari Dmitry Bokov Alexander Markov Abduladheem Turki Jalil Mohammed Nader Shalaby Wanich Suksatan Supat Chupradit Hasan S. AL-Ghamdi Navid Shomali Amir Zamani Ali Mohammadi Mehdi Dadashpour Cancer combination therapies by angiogenesis inhibitors; a comprehensive review Cell Communication and Signaling Angiogenesis Tumor Anti-angiogenic agents Combination therapy Resistance |
| title | Cancer combination therapies by angiogenesis inhibitors; a comprehensive review |
| title_full | Cancer combination therapies by angiogenesis inhibitors; a comprehensive review |
| title_fullStr | Cancer combination therapies by angiogenesis inhibitors; a comprehensive review |
| title_full_unstemmed | Cancer combination therapies by angiogenesis inhibitors; a comprehensive review |
| title_short | Cancer combination therapies by angiogenesis inhibitors; a comprehensive review |
| title_sort | cancer combination therapies by angiogenesis inhibitors a comprehensive review |
| topic | Angiogenesis Tumor Anti-angiogenic agents Combination therapy Resistance |
| url | https://doi.org/10.1186/s12964-022-00838-y |
| work_keys_str_mv | AT mohammadjavedansari cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT dmitrybokov cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT alexandermarkov cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT abduladheemturkijalil cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT mohammednadershalaby cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT wanichsuksatan cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT supatchupradit cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT hasansalghamdi cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT navidshomali cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT amirzamani cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT alimohammadi cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview AT mehdidadashpour cancercombinationtherapiesbyangiogenesisinhibitorsacomprehensivereview |